Structure of pyrazole derivatives impact their affinity, stoichiometry, and cooperative interactions for CYP2E1 complexes

被引:14
|
作者
Hartman, Jessica H. [1 ]
Bradley, Amber M. [2 ]
Laddusaw, Ryan M. [3 ]
Perry, Martin D., Jr. [4 ]
Miller, Grover P. [1 ]
机构
[1] Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA
[2] Vanderbilt Univ, Dept Med, Div Gastroenterol, Nashville, TN USA
[3] Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA
[4] Ouachita Baptist Univ, Dept Chem, Arkadelphia, AR USA
基金
美国国家卫生研究院;
关键词
Cytochrome P450; CYP2E1; Allostery; Cooperativity; Azole; Structure-function; HUMAN CYTOCHROME-P450 2E1; LIGAND-BINDING; ACTIVE-SITE; SUBSTRATE; METABOLISM; DYNAMICS;
D O I
10.1016/j.abb.2013.06.011
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
CYP2E1 plays a critical role in detoxification and carcinogenic activation of drugs, pollutants, and dietary compounds; however, these metabolic processes can involve poorly characterized cooperative interactions that compromise the ability to understand and predict CYP2E1 metabolism. Herein, we employed an array of ten azoles with an emphasis on pyrazoles to establish the selectivity of catalytic and cooperative CYP2E1 sites through binding and catalytic studies. Spectral binding studies for monocyclic azoles suggested two binding events, while bicyclic azoles suggested one. Pyrazole had moderate affinity toward the CYP2E1 catalytic site that improved when a methyl group was introduced at either position 3 or 4. The presence of methyl groups simultaneously at positions 3 and 5 blocked binding, and a phenyl group at position 3 did not improve binding affinity. In contrast, pyrazole fusion to a benzene or cyclohexane ring greatly increased affinity. The consequences of these binding events on CYP2E1 catalysis were studied through inhibition studies with 4-nitrophenol, a substrate known to bind both sites. Most pyrazoles shared a common mixed cooperative inhibition mechanism in which pyrazole binding rescued CYP2E1 from substrate inhibition. Overall, inhibitor affinities toward the CYP2E1 catalytic site were similar to those reported in binding studies, and the same trend was observed for binding at the cooperative site. Taken together, these studies identified key structural determinants in the affinity and stoichiometry of azole interactions with CYP2E1 and consequences on catalysis that further advance an understanding of the relationship between structure and function for this enzyme. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:12 / 20
页数:9
相关论文
共 50 条
  • [21] Refined CYP2E1 Template system to decipher the ligand-interactions
    Yamazoe, Yasushi
    Murayama, Norie
    Yoshinari, Kouichi
    DRUG METABOLISM AND PHARMACOKINETICS, 2021, 41
  • [22] Interactions of inhibitor molecules with the human CYP2E1 enzyme active site
    Martikainen, Laura E.
    Rahnasto-Rilla, Minna
    Neshybova, Silvie
    Lahtela-Kakkonen, Maija
    Raunio, Hannu
    Juvonen, Risto O.
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2012, 47 (05) : 996 - 1005
  • [23] Association of CYP2E1*6 polymorphism of gene CYP2E1 with the risk and severity of chronic hepatitis C
    Godovan, V. V.
    Ostapchuk, K. V.
    ZAPOROZHYE MEDICAL JOURNAL, 2014, (03) : 67 - 70
  • [24] Acetoacetate induces CYP2E1 protein and suppresses CYP2E1 mRNA in primary cultured rat hepatocytes
    Abdelmegeed, MA
    Carruthers, NJ
    Woodcroft, KJ
    Kim, SK
    Novak, RF
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 315 (01): : 203 - 213
  • [25] ETHANOL INDUCES CYP2E1 BY PROTEIN STABILIZATION - ROLE OF UBIQUITIN CONJUGATION IN THE RAPID DEGRADATION OF CYP2E1
    ROBERTS, BJ
    SONG, BJ
    SOH, Y
    PARK, SS
    SHOAF, SE
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (50) : 29632 - 29635
  • [26] Discovery of CYP2E1 as a novel target in rheumatoid arthritis and validation by a new specific CYP2E1 inhibitor
    Han, Zixinying
    Liu, Chenxu
    Li, Mingrui
    Deng, Mengyan
    Ding, Ying
    Li, Yunchao
    Huo, Meidan
    Xu, Haiwei
    Qiao, Hailing
    Gao, Na
    BIOCHEMICAL PHARMACOLOGY, 2024, 229
  • [27] CYP2E1 and clinical features in alcoholics
    Nakamura, K
    Iwahashi, K
    Ameno, K
    Sekine, Y
    Suzuki, K
    Minabe, Y
    Mori, N
    NEUROPSYCHOBIOLOGY, 2003, 47 (02) : 86 - 89
  • [28] CYP2E1 autoantibodies in liver diseases
    Sutti, Salvatore
    Rigamonti, Cristina
    Vidali, Matteo
    Albano, Emanuele
    REDOX BIOLOGY, 2014, 3 : 72 - 78
  • [29] CYP2E1 activity in cirrhosis.
    Villeneuve, JP
    Fournier, C
    Brachemi, S
    Trudel, L
    HEPATOLOGY, 2003, 38 (04) : 701A - 701A
  • [30] Role of CYP2E1 in deramciclane metabolism
    Monostory, K
    Köhalmy, K
    Hazai, E
    Vereczkey, L
    Kóbori, L
    DRUG METABOLISM AND DISPOSITION, 2005, 33 (11) : 1717 - 1722